In my 10 years as a professor, I struggled to find material on contemporary policy issues for my SYLLABUS.
The speed & novelty of today's policy changes impacting trade make the challenge **YOU** face even greater.
Here is a small attempt to help... 1/🧵
Here are four (IV) papers. Each...
• contains a positive explanation of what happened
• leans heavily (and makes available) data
• admittedly raises more questions than it answers
(though, since the policy issues remain unresolved, perhaps that is a feature, not a bug...) 2/
I. COVID-19 VACCINES: How dozens of companies at nearly 100 geographically distributed sites came together to form supply chains to manufacture billions of doses from Pfizer/BioNTech, Moderna, AstraZeneca, Johnson & Johnson, Novavax, and CureVac... 3/
Early in the pandemic, a global shortage of hospital gowns, gloves, masks & respirators caused policymakers to panic. This paper examines PPE trade and policy during the crisis, with a focus on China, the EU and US... 6/ piie.com/publications/w…
The Trump administration changed US trade policy toward China in ways that will take years for researchers to sort out. This paper makes four specific contributions to that research agenda... 9/ piie.com/publications/w…
The US-China trade war forced a reluctant chip industry into someone else’s fight. This paper describes how the political economy of the global semiconductor industry evolved since the 1980s, and what happened in 2018-20... 15/ piie.com/publications/w…
Bown, Chad P., "How the United States marched the semiconductor industry into its trade war with China," East Asian Economic Review v24, n4 (December 2020): 349-388.
On Friday, trade beat reporters for multiple media outlets reported that the Biden administration was considering a new "Section 301" unfair trade investigation of China.
This one reportedly would examine China's industrial subsidies. 1/
The Biden administration is targeting Beijing’s widespread use of industrial subsidies that give its companies an edge over foreign rivals
CureVac's COVID-19 mRNA vaccine may not be salvageable. However, the company's brand new manufacturing supply chain - capable of delivering 1 billion doses - should be. But doing so requires creative industry / policymaker collaboration.
On April 15, CureVac had announced its supply chain was on track to manufacture 300 million doses of its mRNA vaccine by the end of 2021 and another 1 billion doses in 2022, upon regulatory approval.
How in the world did we end up with billions of doses of COVID-19 vaccines manufactured by Pfizer/ BioNTech, Moderna, AstraZeneca, and Johnson & Johnson?
Roughly 4 billion doses of COVID-19 vaccines have now been administered worldwide. Most required a two-dose regimen—if that trajectory continued, close to 14 billion shots would be needed to inoculate the global population. 2/
Getting a new vaccine from beginning to end — from concept to delivering shots into the public’s arms — requires five steps associated with five, largely separable, sets of fixed costs. 3/
COVID-19 meant devastating shortages of personal protective equipment (PPE), like masks, gowns and gloves. What happened to trade, the unprecedented trade and industrial policy to emerge, as well as lessons learned for future preparedness.
Chip shortage! The Biden administration and US allies have now committed to work together on semiconductor policy. That will prove hard. Why it's needed, and where to start.
The chip shortage facing automakers heightened the issue's seriousness. But the supply of semiconductors was at risk long before the pandemic, and COVID-19 is only partly to blame for today’s problems.
One of the biggest culprits was a sudden shift in US trade policy... 2/
Trump imposed 25% trade war tariffs on semiconductors beginning in July 2018. The US now imports **half as many** semiconductors from China as it did pre-trade war. (That's billions of fewer chips).
Those missing chips have NOT been replaced by imports from elsewhere... 3/